ORIGINAL ARTICLE |
|
Year : 2015 | Volume
: 52
| Issue : 6 | Page : 69-74 |
Percutaneous computed tomography-guided iodine-125 seeds implantation for unresectable pancreatic cancer
B Liu1, T Zhou2, J Geng3, F Zhang4, J Wang5, Y Li6
1 Department of Interventional Medicine, The Second Hospital of Shandong University, Jinan, Shandong Province, PR of, China 2 Postgraduate student of Medical College, Shandong University, Jinan, PR of, China 3 Department of Hepatobiliary Surgery, Weihai Municipal Hospital, Shandong Province, Jinan, PR of, China 4 Department of Medical Imaging and Interventional Radiology, Cancer Center and State Key Laboratory of Oncology in South , Sun Yat-sen University, Guangzhou, Guangdong, PR of, China 5 Department of Radiation Oncology, Cancer Centre, Peking University Third Hospital, Beijing, PR of, China 6 Department of Interventional Medicine, The Second Hospital of Shandong University, Shandong, Shandong Province, PR of, China
Correspondence Address:
Y Li Department of Interventional Medicine, The Second Hospital of Shandong University, Jinan, Shandong Province China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0019-509X.172517
Background: To examine the safety and clinical efficacy of computed tomography (CT)-guided radioactive iodine-125 (125I) seeds implantation for patients with unresectable pancreatic cancer. Materials and Methods: A group of 26 patients with pathologically confirmed unresectable pancreatic cancer underwent percutaneous CT-guided 125I seeds implantation. Part of them received transarterial chemotherapy and/or percutaneous transhepatic cholangial drainage before or after seeds implantation. The primary endpoints were the objective response rates, local control rates, and overall survival. Results: CT scan 2 months after treatment revealed complete response (CR) in 8 patients, partial response (PR) in 9 patients. Overall response rate (CR + PR) is 65.38%. Local control rate was 88.46%. Median survival of the whole group was 15.3 months, whereas for Stage III and IV was 17.6 and 9.1 months, respectively. The estimated 1-year survival was 30.77%. Conclusions: We consider CT-guided 125I seeds implantation as a safe, effective, uncomplicated treatment for unresectable pancreatic cancer.
[FULL TEXT] [PDF]*
|